Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Infectious disease

Tuberculosis

Unknown

In vitro studies suggest a modified oxyphenbutazone (OPB) could help treat tuberculosis. Nonreplicating Mycobacterium tuberculosis (Mtb) can become resistant to therapeutics that target replicating Mtb. In a high throughput screen, the generic anti-inflammatory drug OPB killed nonreplicating Mtb but not replicating Mtb under acidic conditions. In liquid culture, a 4-hydroxylated OPB decreased growth of both replicating and nonreplicating Mtb compared with vehicle and acted synergistically with other antimicrobials. Next steps include clinical trials.
OPB is a generic NSAID.

SciBX 5(38); doi:10.1038/scibx.2012.1010
Published online Sept. 27, 2012

Findings unpatented; licensing status not applicable

Gold, B. et al. Proc. Natl. Acad. Sci. USA; published online Sept. 10, 2012;
doi:10.1073/pnas.1214188109
Contact: Carl F. Nathan, Weill Cornell Medical College, New York, N.Y.
e-mail:
cnathan@med.cornell.edu